Chen Yu

Chen Yu jumps ship from Vi­vo Cap­i­tal and goes large, al­ly­ing with The Col­umn Group on an in­au­gur­al $824M biotech crossover fund

Over the past 15 years, the crew at The Col­umn Group have gath­ered more than $2 bil­lion to­geth­er to pur­sue their game plan of fos­ter­ing biotech star­tups. And it’s been ef­fec­tive. Their port­fo­lio plays have pro­vid­ed a tar­get-rich en­vi­ron­ment for big play­ers like Roche and J&J and Ver­tex to come stalk­ing ac­qui­si­tions.

Re­cent­ly, though, one of the man­ag­ing part­ners at Vi­vo Cap­i­tal jumped ship af­ter a very long tenure — 17 years — and went on to quick­ly cre­ate a brand new biotech fund they’re part­nered with the VC on called TCG Crossover; TCG X in ab­bre­vi­at­ed fash­ion. His name is Chen Yu, and in the midst of the busiest crossover sea­son in the in­dus­try’s his­to­ry, he’s jump­ing in to the game with an $824 mil­lion stake that will be put in­to play at the junc­tion in­ter­sect­ing biotechs with pub­lic mar­kets — with a spe­cial side fo­cus on the boom­ing Chi­na mar­ket, where he’s been a play­er for years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.